Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sensitizing Potential of LEO 43204 Gel in Healthy Volunteers
NCT02650505Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Feb 2016
- Primary completion
- Jun 2016
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in actinic keratosis (AK) comparing LEO 43204 with Vehicle (2 arms). Primary endpoint: Determination of dermal sensitization based on Local Skin Reactions (LSRs) at 8 weeks. Started Feb 2016; status: completed.
02
Drugs
ingenol disoxate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02650505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02650505.